Uutiset-näyttösivun murupolku en
List of interchangeable medicinal products 1 April-30 June 2023
The Finnish Medicines Agency Fimea has confirmed the list of interchangeable medicinal products for the period 1 April to 30 June 2023.
A total of 156 medicinal products have been added to the list that will enter into force at the beginning of April.
138 generic medicines have been added to the list. The mineral sodium chloride has been added to the list as a new product.
18 products have been added to the scope of parallel import or parallel distribution. The list includes new products, such as a medicine for respiratory tract disease, a combination of ivacaftor and tezacaftor, and an ophthalmological medicine in the form of a dexamethasone and antimicrobials compound.
1.1. the list has been expanded on the basis of an amendment to section 57c, subsection 1 of the Medicines Act (in Finnish), which entered into force in 2023 a total of 62 inhalation products for the treatment of asthma or COPD .
A total of 81 medicinal products have been removed from the list due to the withdrawal of their marketing authorisation.
The list contains a total of 6,289 medicinal products and these represent a total of 753 active substances or groups of compounds calculated in different ATC groups. The largest number of products with marketing authorisation include: pregabalin (121), which affects the nervous system, antipsychotic olanzapine (109), cancer medicine lenalidomide (107), dementia medicine rivastigmine (66), anti-psychotic aripiprazole (64), pramipexole, a medicine for Parkinson's (62), antipsychotic quetiapine (58), cancer medicine temozolomide (56) and diabetes medicine sitagliptin (55). Around 62 per cent of all medicinal products with marketing authorisations in Finland, which are intended for human use are in the scope of interchangeable medicines. There are a total of 10,064 such products.
Interchangeable medicinal products (in Finnish)
Notice (Kela, Pharmaceutical Pricing Board and Fimea): Reference price groups for inhaled medications to be expanded on 1 April 2023
Ask more
- Marjo-Riitta Helle, Head of Unit, tel. +358 29 522 3320 (principles for drawing up the list)
- Jukka Sallinen, Head of Unit, tel. +358 29 522 3410 (principles for drawing up the list)
- Juuso Haasto, Legal Counsel, tel. +358 29 522 3643 (principles for drawing up the list)
- Merja Laakso, Coordinator for Marketing Authorisations, tel. +358 29 522 3368 (the file that can be downloaded into a database)
- Jenni Sääskilahti, Coordinator for Marketing Authorisation , tel. +358 29 522 3438 (the file that can be downloaded into a database)
- E-mails take the form [email protected]